Relugolix Completed Phase 2 Trials for Uterine Leiomyomas Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01452659Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids